Overview

The global Losartan potassium market was valued at USD 1.64 billion in 2025 and is projected to reach USD 3.65 billion by 2034, growing at a CAGR of 4.2% during the forecast period (2026–2034). The market is driven by the rising prevalence of hypertension and cardiovascular disease, an aging population, affordable generic medicines, and growing healthcare coverage in emerging markets. Losartan potassium is an angiotensin II receptor blocker used to treat high blood pressure, protect kidney function in diabetic patients, reduce cardiovascular risk, and it is available in tablets, oral suspension, and capsules across hospital, retail, and online channels.

 

The market is shifting from branded Losartan toward low-cost generic versions following patent expiry, growing move toward patient-friendly formulations, combination therapies, and digital and home-based healthcare systems focus on affordability and chronic disease management.

 

Government and health initiatives like World Health Organization Essential Medicines List, includes Losartan and supports its global use, India’s production-linked incentive scheme for pharmaceuticals, strengthens domestic drug manufacturing, and the United States Generic Drug User Fee program speeds generic approvals increasing the demand for Losartan potassium. Also, The U.S. FDA approved the first ready -to-use Liquid Losartan Formulation.

 

By region, North America holds the largest share of the market, supported by high hypertension prevalence, strong healthcare infrastructure, and wide generic adoption, while Asia-Pacific is the fastest-growing region as rising cardiovascular disease, a large and aging population, expanding healthcare access, and growing pharmaceutical manufacturing increase demand.

Market Size & Share

Market Dynamics

Expansion of Generic Drug Manufacturing Is the Key Trend

• Rising hypertension prevalence, growing healthcare cost-containment efforts, and increasing demand for affordable cardiovascular medicines supports governments and pharmaceutical companies to expand generic drug production.
• Companies are adopting backward integration strategies for APIs and drug intermediates to improve production efficiency, regulatory compliance, and long-term supply security.
• The Indian government reported 55 pharmaceutical companies selected under pharmaceutical manufacturing incentive programs to expand production of APIs, generic drugs, and other high-value medicines.
• The India–New Zealand Free Trade Agreement, finalized in late 2025, provides access for pharmaceutical exports and strengthens the global generic medicine supply chain.

 

Favourable Clinical Profile and Guideline Recommendations Is the Key Driver

• Because it lowering blood pressure, reducing stroke risk, and protecting kidney function in patients with diabetes and chronic kidney disease (CKD). Also, recommend ARBs, including losartan, as first-line treatment options for hypertension and diabetic nephropathy.
• International CKD management initiatives led by organizations such as KDIGO continue to emphasize blood-pressure control and renin-angiotensin system blockade to reduce kidney disease progression
• The World Health Organization HEARTS technical package supports standardized hypertension management that includes angiotensin receptor blockers, which supports broad prescribing.
• Companies entered with strategic collaborations with healthcare distribution and patient-access platforms to improve prescription fulfillment and treatment initiation.

 

Growing Demand in Emerging Healthcare Markets Is the Key Opportunity

• Because of rising populations, growing of chronic diseases, increasing health insurance coverage, and improved access to medical services increases demand for medical devices, pharmaceutical packaging, diagnostic equipment, and disposable healthcare products all rely heavily on polymers.
• Also, polymers are used in syringes, IV bags, catheters, implants, drug-delivery systems, and sterile packaging due to their lightweight nature, biocompatibility, durability, and cost friendly.
• Many emerging countries like India, China, Indonesia, Brazil, Vietnam, Saudi Arabia supports their domestic production of medical devices and healthcare equipment to reduce import dependency.
• In China, Healthcare modernization and Medical Technology Development invest in healthcare infrastructure, domestic medical technology manufacturing and advanced healthcare materials.
• Brazil’s Farmácia Popular program subsidizes medicines and improves access to particularly low-income households. This program operate’s partnerships with public and private pharmacies.

Global Losartan Potassium Market Size, 2025–2034 (USD Billion)

Segmentation Analysis

Analysis by Dosage Form

The tablets segment held the largest market share in 2025. Because they are low cost, easy to manufacture at scale, stable, and accurately dosed, makes them the standard form for long-term medication. Demand increases from the large population of hypertension and cardiovascular patients take a daily oral dose. The United Kingdom National Health Service and NICE generic prescribing guidance supports the use of low-cost tablet generics. Japan’s generic drug substitution policy supports the use of tablet generics over branded products.

 

The oral suspension segment will grow at the fastest CAGR during the forecast period. Because it is easier to swallow and allows flexible dosing, suits patients who cannot take tablets. Rising demand of pediatric, geriatric, and dysphagia patients need adjustable doses. United States Food and Drug Administration pediatric drug development incentives supports the development of suspension formulations. The European Union Paediatric Regulation, requires age-appropriate formulations, encouraging suspension development.

 

Dosage form categories include:

•      Tablets (Largest Category)

•      Oral Suspension (Fastest-Growing Category)

•      Capsules

•      Others

 

Analysis by Distribution Channel

The retail pharmacies segment held the largest market share in 2025. Because they are refilling chronic prescriptions such as Losartan, with wide reach and convenient locations. Rising demand from long-term hypertension patients refill their medication regularly at retail outlets. India’s Jan Aushadhi generic medicine store program expands affordable retail access to essential drugs. The United States Medicare Part D program supports outpatient retail prescription coverage for many patients. Convenience and proximity to patients continue to support steady, high-volume sales.

 

The online pharmacies segment will grow at the fastest CAGR during the forecast period. Because they offer home delivery, subscription refills, and price transparency, suit patients on long-term medication. Demand is rising from digitally engaged and chronic patients  prefer convenient refills. China’s internet hospital and online pharmacy policy supports regulated digital prescribing and dispensing. Singapore’s Health Sciences Authority e-pharmacy framework enables regulated online dispensing.

 

Distribution channel categories include:

•      Retail Pharmacies (Largest Category)

•      Online Pharmacies (Fastest-Growing Category)

•      Hospital Pharmacies

•      Drug Stores

 

Analysis by Sales Channel

The prescription-based drugs segment held the largest market share in 2025. Rising demand is driven by diagnosed hypertension and cardiovascular patients on long-term therapy. Australia’s Pharmaceutical Benefits Scheme subsidizes prescription medicines and supports steady prescription volume. Germany’s statutory health insurance reimbursement covers prescription drugs for most of the population. Ongoing chronic disease management ensures consistent, large-volume prescription sales.

 

The generic drugs segment will grow at the fastest CAGR during the forecast period. Because they offer the same efficacy at much lower cost after patent expiry, drives rapid substitution. Demand is rising from payers, governments, and patients seeking affordable hypertension treatment. The United States Hatch-Waxman Act and Drug Competition Action Plan fast the generic approvals and competition. South Korea’s generic drug pricing and incentive policy supports the use of generics. Expanding manufacturing in India and China lowers cost and increases supply, which sustains fast growth.

 

Sales channel categories include:

•      Prescription-Based Drugs (Largest Category)

•      Generic Drugs (Fastest-Growing Category)

•      Branded Drugs

 

Analysis by End User

The hospitals segment held the largest market share in 2025. Hospitals manage acute and complex hypertension, cardiovascular, and renal cases, and they prescribe and dispense Losartan at scale. Demand comes from inpatient care and from discharge prescriptions for ongoing therapy. Saudi Arabia’s centralized medical procurement program supplies hospitals with essential medicines, including Losartan. Integrated pharmacy services, bulk procurement, and specialist care further support their position. South Africa’s public hospital essential medicines procurement strengthens reliable hospital supply. Rising hospital admissions for cardiovascular disease continue to support high-volume use.

 

The homecare settings segment will grow at the fastest CAGR during the forecast period because they allows chronic patients to manage their daily oral medication at home, lowers cost and reduces hospital visits. Demand is rising from aging populations and the shift toward home-based chronic disease management. Japan’s community-based integrated care system supports home healthcare for the elderly. United States home health programs under public reimbursement support home-based care

 

End user categories include:

•      Hospitals (Largest Category)

•      Homecare Settings (Fastest-Growing Category)

•      Specialty Clinics

•      Ambulatory Surgical Centers

•      Others

Regional Analysis

North America held the largest market share at over XX% in 2025, because of the high prevalence of hypertension and cardiovascular disease, strong healthcare infrastructure, wide insurance coverage, and high adoption of generic medicines. The United States leads with large patient populations and an established generic supply base, while Canada and Mexico support steady demand through public health systems and growing generic use.

 

Asia-Pacific is the fastest-growing regional market, because of rising hypertension and cardiovascular disease, a large and aging population, expanding healthcare access, and growing pharmaceutical manufacturing. China and India are major producers of generic Losartan and active ingredients, while Japan and South Korea support demand through advanced healthcare systems, and Europe maintains steady demand supported by aging populations and established generic prescribing.

 

Countries and regions include:

·         North America (Largest Regional Market)

o    U.S. (Largest Country Market)

o    Canada

o    Mexico

·         Asia-Pacific (Fastest-Growing Regional Market)

o    China (Largest Country Market)

o    India (Fastest-Growing Country Market)

o    Japan

o    Rest of APAC

·         Europe

o    Germany (Largest Country Market)

o    France

o    U.K.

o    Rest of Europe

·         Latin America

o    Brazil (Largest Country Market)

o    Rest of LATAM

·         Middle East and Africa

o    Saudi Arabia (Largest Country Market)

o    UAE (Fastest-Growing Country Market)

o    Rest of MEA

Market Share

The global Losartan potassium market is fragmented because Losartan is off-patent and produced by many generic manufacturers worldwide. Companies such as Merck, Organon, Teva Pharmaceutical Industries, Sandoz, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin, Cipla, and Torrent Pharmaceuticals are among the leading producers, competing on price, quality, regulatory approvals, and supply reliability. Companies are expanding through new generic approvals, capacity additions, combination products, and supply agreements to secure market position and meet rising demand. Strict regulatory standards, bioequivalence requirements, and price competition shape the market and favor large manufacturers with strong quality and cost advantages.

 

Key Players Covered

•      Merck & Co., Inc. (U.S.)

•      Organon & Co. (U.S.)

•      Teva Pharmaceutical Industries Ltd. (Israel)

•      Sandoz Group AG (Switzerland)

•      Viatris Inc. (U.S.)

•      Sun Pharmaceutical Industries Ltd. (India)

•      Dr. Reddy’s Laboratories Ltd. (India)

•      Aurobindo Pharma Limited (India)

•      Lupin Limited (India)

•      Cipla Limited (India)

•      Torrent Pharmaceuticals Ltd. (India)

•      Zydus Lifesciences Limited (India)

•      Hikma Pharmaceuticals PLC (U.K.)

•      Krka, d.d. (Slovenia)

•      Granules India Limited (India)

 

Market News

• In 2024, Granules India received U.S. FDA approval for additional Losartan potassium tablet strengths, expanding its generic portfolio in the United States.
• In March 2025, Sun Pharmaceutical expanded its cardiovascular generics manufacturing capacity to meet rising global demand for antihypertensive medicines.
• In February 2025, Dr. Reddy’s Laboratories launched a Losartan potassium combination product to broaden its hypertension treatment portfolio.
• In January 2025, Teva Pharmaceutical expanded supply agreements for generic antihypertensive medicines, including Losartan, in emerging markets.
• In 2024, Aurobindo Pharma increased its active pharmaceutical ingredient capacity for cardiovascular drugs to support growing generic Losartan production.

Frequently Asked Questions